View in EDS

Controlled release and bioactivity of the monoclonal antibody rituximab from a porous matrix: A potential in situ therapeutic device.

Saved in:
Bibliographic Details
Title: Controlled release and bioactivity of the monoclonal antibody rituximab from a porous matrix: A potential in situ therapeutic device.
Authors: Simovic, S.1, Diener, K.R.2,3,4, Bachhuka, A.5, Kant, K.6, Losic, D.6, Hayball, J.D.3,4,7, Brownc, M.P.3,4,7,8, Vasilev, K.5 Krasimir.Vasilev@unisa.edu.au
Source: Materials Letters. Sep2014, Vol. 130, p210-214. 5p.
Subjects: Monoclonal antibodies, Rituximab, Porous materials, Polymer films, Chemical kinetics, Plasma polymerization
Abstract: Abstract: We report on a platform for extended release of biologically-active therapeutic antibodies. Extended antibody release has been achieved by utilising a plasma polymer film of controlled and predetermined thickness deposited on the top of a porous platform loaded with rituximab. Antibody release kinetics directly correlates to the plasma polymer film thickness that is in turn controlled by the plasma polymer deposition time. After 1 month, 82%, 60% and 45% of the antibody is released from platforms coated with plasma polymer for 50s, 150s and 300s, respectively. Activity of the released antibody was assessed in cultures of CD20-positive Daudi cells by using polyacrylamide gel electrophoresis and flow cytometry. The results from gel electrophoresis and flow cytometry indicate that the antibody had maintained its integrity during the release process. This work provides a proof-of-concept technology that achieves extended release of biologically active rituximab for more than 30 days. [Copyright &y& Elsevier]
Copyright of Materials Letters is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:Abstract: We report on a platform for extended release of biologically-active therapeutic antibodies. Extended antibody release has been achieved by utilising a plasma polymer film of controlled and predetermined thickness deposited on the top of a porous platform loaded with rituximab. Antibody release kinetics directly correlates to the plasma polymer film thickness that is in turn controlled by the plasma polymer deposition time. After 1 month, 82%, 60% and 45% of the antibody is released from platforms coated with plasma polymer for 50s, 150s and 300s, respectively. Activity of the released antibody was assessed in cultures of CD20-positive Daudi cells by using polyacrylamide gel electrophoresis and flow cytometry. The results from gel electrophoresis and flow cytometry indicate that the antibody had maintained its integrity during the release process. This work provides a proof-of-concept technology that achieves extended release of biologically active rituximab for more than 30 days. [Copyright &y& Elsevier]
ISSN:0167577X
DOI:10.1016/j.matlet.2014.05.110